Article: Adprotech Being Acquired By Inflazyme In C$20M Deal.(Inflazyme Pharmaceuticals Ltd)

Article: Inflazyme Reports Negative Outcome of Phase IIa ...
Business Wire;  June 18, 2004 ;     700+ words ... ... Pharmaceuticals Ltd. (TSX:IZP) today announced the results of the Phase IIa study comparing its LSAID(TM) (Leukocyte Selective Anti ... technologies, recently obtained through the acquisition of Adprotech, and ATH. We will continue to manage our cash resources ...

Article: Adprotech Being Acquired By Inflazyme In C$20M Deal.
BIOWORLD Today;  November 3, 2009 ;     700+ words ... ... The acquisition of Adprotech by Inflazyme, of Vancouver ... technology, a compound in Phase IIa trials in rheumatoid ... in Cambridge-based Adprotech: 3i plc, Alice Ventures ... further modified with Adprotech's Prodaptin targeting ... complement cascade. The Phase IIa study under way ...

Article: Inflazyme Completes Acquisition of Adprotech Ltd.
Business Wire;  April 20, 2004 ;     700+ words ... ... Inflazyme common shares. Adprotech shareholders have agreed to ... completion of the acquisition. Adprotech Ltd. is a biotechnology company ... many different diseases. Adprotech has a portfolio of complement ... 602, is currently in a Phase IIa asthma clinical trial being ...

Article: US FDA grants Adprotech's APT070 Orphan Drug Status in ...
Pharma Marketletter;  June 30, 2003 ;     319 words ...The US Food and Drug Administration has granted Adprotech's APT070 Orphan Drug Status for the prevention of delayed ... organ prior to transplantation. APT070 is currently in Phase IIa evaluation for transplant rejection and is also undergoing ...

Article: MDS Harris Expanding Phase IIa Capabilities.
PR Newswire;  January 12, 1999 ;     700+ words ... ... Striving to be World-Leading provider of Phase IIa in Specific Therapeutic Areas LINCOLN ... develop specific expertise in conducting Phase IIa studies for selected therapeutic areas ... have been revealed much earlier during Phase IIa studies," Curtis said. "As a result ...

Article: CytRx Successfully Completes Patient Dosing and Follow-Up in ...
Business Wire;  July 24, 2006 ;     700+ words ... ... up with arimoclomol in the Company's Phase IIa clinical trial for the treatment of amyotrophic ... sclerosis (ALS or Lou Gehrig's disease). Phase IIa patients were evaluated while receiving ... expects to complete data analysis of the Phase IIa trial and announce final results early ...

Article: rNAPc2 Phase IIa Clinical Trial Data Are ...
Heart Disease Weekly;  January 6, 2002 ;     700+ words ... ... Inc., announced that results from a Phase IIa clinical study show that the anticoagulant ... clot. The complete data set from this Phase IIa trial were presented on December 10 ... and stent placement, we believe these Phase IIa results support our plan to initiate ...